Longer-Term TOBI Interim Data to be Presented At European Cystic Fibrosis Meeting
08:14 a.m. Jun 16, 1998 Eastern

BERLIN, June 16 /PRNewswire/ -- Longer-term interim data on TOBI(R) (tobramycin solution for inhalation) will be presented today at a satellite meeting of the 22nd European Cystic Fibrosis Conference, sponsored by the University Children's Hospital, Charite', Berlin. TOBI was introduced in the U.S. last January by PathoGenesis Corp.

The interim data showed that patients who had been on TOBI for 11 months maintained a level of improvement in lung function similar to that achieved at the end of the six-month Phase III clinical trials. Interim data on patients who had been on placebo and began taking TOBI after the conclusion of the Phase III clinical trials showed initial lung function improvement similar to what was seen in the Phase III clinical trials. The data will be presented by Bonnie W. Ramsey, M.D., professor of pediatrics at the University of Washington, Seattle.

"I am very encouraged that the clinical improvement seen in the six-month trials has been maintained," said Dr. Ramsey, principal investigator for the TOBI clinical trials.

In addition, 18-month TOBI data are expected to be presented at the North American Cystic Fibrosis Conference, Oct. 15-18 in Montreal.

Each ready-to-use ampule of TOBI contains 300 milligrams of tobramycin in a 5 milliliter solution. TOBI is aerosolized and administered using a PARI LC PLUS(TM) reusable nebulizer and a DeVilbiss Pulmo-Aide(R) air compressor. It is inhaled twice daily and requires about 15 minutes per treatment. The TOBI treatment regimen consists of repeated cycles of 28 days on drug, followed by 28 days off drug.

Seattle-based PathoGenesis Corp. develops drugs for treating serious infectious diseases where there is a significant need for improved therapy. The company markets an inhaled antibiotic in the U.S. and is developing drug candidates to treat lung infections in cystic fibrosis, bronchiectasis and tuberculosis patients. PathoGenesis' stock is traded on the Nasdaq National Market System under the symbol PGNS. The company's Web site is located at www.pathogenesis.com.

Note: This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to known and unknown risks, uncertainties or other factors that may cause the company's actual results to be materially different from historical results or any results expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to the fact that PathoGenesis began commercial operations only recently, its dependence on TOBI, third party reimbursement and product pricing, government regulation, drug development and clinical trials, competition and alternative therapies, and other factors described in PathoGenesis' filings with the Securities and Exchange Commission. SOURCE PathoGenesis Corp.

Copyright 1998, PR Newswire

Volver a Medios de Comunicación